Edition:
India

Qiagen NV (QIA.DE)

QIA.DE on Xetra

30.60EUR
20 Sep 2019
Change (% chg)

€-0.12 (-0.39%)
Prev Close
€30.72
Open
€30.74
Day's High
€30.75
Day's Low
€30.43
Volume
1,096,581
Avg. Vol
445,541
52-wk High
€37.03
52-wk Low
€29.01

Latest Key Developments (Source: Significant Developments)

Qiagen Announces Change In Global Sales Structure
Tuesday, 10 Sep 2019 

Sept 10 (Reuters) - Qiagen NV ::QIAGEN ANNOUNCES CHANGE IN GLOBAL SALES STRUCTURE.DECIDED TO INTEGRATE ITS GLOBAL SALES RESOURCES INTO ITS BUSINESS AREAS (LIFE SCIENCES, MOLECULAR DIAGNOSTICS AND BIOINFORMATICS).PLANS TO PROVIDE AN UPDATE DURING Q4 OF 2019.MANUEL O. MENDEZ, SENIOR VICE PRESIDENT, GLOBAL COMMERCIAL OPERATIONS AND A MEMBER OF EXECUTIVE COMMITTEE, HAS RESIGNED TO ACCEPT A NEW CAREER OPPORTUNITY, AND LEAVE COMPANY IN OCTOBER 2019.  Full Article

Qiagen Affirms Q2 Results
Wednesday, 31 Jul 2019 

July 31 (Reuters) - Qiagen::Results remain unchanged from those announced July 24.Qiagen delivers on Q2 2019 outlook.Net sales of $381.6 million.Diluted EPS of $0.19.  Full Article

Qiagen's Says Now Expects Full-Year 2019 Net Sales Growth Of About 5-6% CER
Thursday, 25 Jul 2019 

July 24 (Reuters) - Qiagen NV ::DGAP-ADHOC: QIAGEN N.V. QIAGEN'S RESULTS FOR SECOND QUARTER 2019 IN LINE WITH OUTLOOK AT CER, REVISED FULL-YEAR 2019 OUTLOOK DUE TO INTENDED RESTRUCTURING OF CHINA NGS PARTNERSHIP.QIAGEN NV SAYS QIAGEN NOW EXPECTS FULL-YEAR 2019 NET SALES GROWTH OF APPROXIMATELY 5-6% CER (PREVIOUSLY ABOUT 7-8% CER).QIAGEN NV SAYS NOW EXPECTS FY 2019 ADJUSTED DILUTED EPS OF APPROXIMATELY $1.42-1.44 CER PER SHARE (PREVIOUSLY ABOUT $1.45-1.47 CER).QIAGEN- CO INTENDS TO RESTRUCTURE CURRENT FORMAT OF ITS NGS PARTNERSHIP IN CHINA DUE TO SLOWER-THAN-EXPECTED UPTAKE OF INVITRO DIAGNOSTIC CLINICAL SEQUENCING.QIAGEN NV SAYS FOR Q3 OF 2019, QIAGEN EXPECTS NET SALES TO GROW APPROXIMATELY 4-5% CER.QIAGEN NV SAYS FOR Q3 OF 2019 ADJUSTED DILUTED EPS IS EXPECTED TO BE ABOUT $0.35-0.36 CER PER SHARE.  Full Article

Qiagen Qtrly Diluted EPS Of $0.13
Tuesday, 7 May 2019 

May 6 (Reuters) - Qiagen NV ::QIAGEN REPORTS RESULTS FOR FIRST QUARTER OF 2019 AND ANNOUNCES PLANS FOR NEW $100 MILLION SHARE REPURCHASE PROGRAM.QTRLY DILUTED EPS OF $0.13; ADJUSTED. EPS OF $0.27.NEW $100 MILLION SHARE REPURCHASE PROGRAM PLANNED.QTRLY NET SALES OF $348.7 MILLION, UP 1.5% ACTUAL.REAFFIRMS 2019 OUTLOOK FOR GROWTH IN NET SALES AND ADJUSTED EPS.Q1 EARNINGS PER SHARE VIEW $0.26, REVENUE VIEW $351.6 MILLION -- REFINITIV IBES DATA.FY2019 EARNINGS PER SHARE VIEW $1.46, REVENUE VIEW $1.60 BILLION -- REFINITIV IBES DATA.  Full Article

Qiagen Acquires U.S. Molecular Decision Support N-Of-One Company
Monday, 7 Jan 2019 

Jan 7 (Reuters) - Qiagen NV ::QIAGEN ACQUIRES N-OF-ONE, EXPANDING ITS CLINICAL BIOINFORMATICS CAPABILITIES IN MOLECULAR ONCOLOGY DECISION SUPPORT.ACQUIRE N-OF-ONE, INC., A PRIVATELY-HELD U.S. MOLECULAR DECISION SUPPORT COMPANY.N-OF-ONE'S TECHNOLOGY-ENABLED, YET HUMAN-DRIVEN, SERVICES AND PROPRIETARY MARKERMINE™ DATABASE ARE PLANNED TO BE INTEGRATED INTO QIAGEN CLINICAL INSIGHT (QCI).  Full Article

Qiagen Announces New Collaboration With Novartis
Thursday, 6 Dec 2018 

Dec 6 (Reuters) - Qiagen NV ::QIAGEN ANNOUNCES NEW COLLABORATION TO DEVELOP COMPANION DIAGNOSTIC TO GUIDE TREATMENT FOR PATIENTS WITH PIK3CA-MUTATED ADVANCED BREAST CANCER.QIAGEN - TO COLLABORATE WITH NOVARTIS TO DEVELOP COMPANION DIAGNOSTIC TO GUIDE TREATMENT FOR PATIENTS WITH PIK3CA-MUTATED ADVANCED BREAST CANCER.  Full Article

Blocktrade - Qiagen Bookrunner Says Deal Upsized To $500 Mln On Convertible Notes
Tuesday, 6 Nov 2018 

Nov 6 (Reuters) - Qiagen's Bookrunner::BLOCKTRADE - QIAGEN: BOOKRUNNER SAYS DEAL UPSIZED TO $500M; BOOKS TO CLOSE AT 13.30 UK.  Full Article

Qiagen Convertible Notes Bookrunner Says Orders Below 1 Pct Coupon & 27.5 Pct Premium Risk Missing
Tuesday, 6 Nov 2018 

Nov 6 (Reuters) - Qiagen's Bookrunner Says::BLOCKTRADE - QIAGEN: BOOKRUNNER SAYS ORDERS BELOW 1.00 PERCENT COUPON AND 27.5 PERCENT PREMIUM RISK MISSING; BOOKS CLOSE AT 12:30PM UKT.  Full Article

Qiagen Bookrunner Says Books Are Covered On Convertible Notes
Tuesday, 6 Nov 2018 

Nov 6 (Reuters) - Qiagen NV's Bookrunner::BLOCKTRADE - QIAGEN: BOOKRUNNER SAYS BOOKS ARE COVERED, FURTHER GUIDANCE TO FOLLOW.  Full Article

Qiagen Announces Convertible Notes Offer
Tuesday, 6 Nov 2018 

Nov 6 (Reuters) - Qiagen NV ::SAYS LAUNCHES NON-US OFFERING OF CASH SETTLED CONVERTIBLE NOTES COMBINED WITH CONVERTIBLE NOTE HEDGE AND WARRANT TRANSACTIONS.INTENDS TO PLACE NOTES IN AN AGGREGATE VOLUME OF $400 MILLION.NUMBER OF ORDINARY SHARES OF QIAGEN UNDERLYING NOTES WILL BE UP TO 8.5 MILLION, REPRESENTING APPROXIMATELY 3.8% OF CURRENT OUTSTANDING SHARES.INTENDS TO USE PROCEEDS FROM ISSUANCE OF NOTES FOR GENERAL CORPORATE PURPOSES.NOTES WILL HAVE A MATURITY OF 6 YEARS, WILL BE ISSUED AND REDEEMED AT 100% OF THEIR PRINCIPAL AMOUNT, PAY A COUPON BETWEEN 0.75% - 1.25% P. A..INITIAL CONVERSION PRICE WILL BE SET AT A CONVERSION PREMIUM OF 27.5%.  Full Article